Article Text

Download PDFPDF

681 A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
  1. Christine Chung1,
  2. Dimitrios Colevas2,
  3. Douglas Adkins3,
  4. Jong Chul Park4,
  5. Cristina Rodriguez5,
  6. Michael Gibson6,
  7. Ammar Sukari7,
  8. Barbara Burtness8,
  9. Faye Johnson9,
  10. Ricklie Julian10,
  11. Nabil Saba11,
  12. Lara Dunn12,
  13. Tanguy Seiwert13,
  14. Francis Worden14,
  15. Rami Haddad15,
  16. Nashat Gabrail16,
  17. Julie Bauman17,
  18. Laura Agensky18,
  19. Apollina Goel18,
  20. Reena Lynam18,
  21. Steven Margossian18,
  22. Raymond Moniz18,
  23. Steve Quayle18,
  24. Cynthia Rajan18,
  25. Kenneth Pienta13,
  26. Matteo Levisetti18 and
  27. Sara Pai4
  1. 1H. Lee Moffitt Cancer Center, Tampa, FL, USA
  2. 2Stanford University School of Medicine, Stanford, CA, USA
  3. 3Washington University School of Medicine, St Louis, MO, USA
  4. 4Massachusetts General Hospital, Boston, MA, USA
  5. 5University of Washington, Seattle, WA, USA
  6. 6Vanderbilt University Medical Center, Nashville, TN, USA
  7. 7Karmanos Cancer Center, Detroit, MI, USA
  8. 8Yale School of Medicine, New Haven, CT, USA
  9. 9The University of Texas MD Anderson, Houston, TX, USA
  10. 10University of Arizona Cancer Center, Tucson, AZ, USA
  11. 11Emory University, Atlanta, GA, USA
  12. 12Memorial Sloan Kettering Cancer Center, New York, NY, USA
  13. 13Johns Hopkins University, Baltimore, MD, USA
  14. 14University of Michigan, Ann Arbor, MI, USA
  15. 15Affiliated Oncologists, LLC, Chicago Ridge, IL, USA
  16. 16Gabrail Cancer and Research Center, Canton, OH, USA
  17. 17George Washington University Cancer Center, Tucson, DC, USA
  18. 18Cue Biopharma Inc, Boston, MA, USA


Background Immuno-STATsTM are modular fusion proteins designed for the selective delivery of IL-2 to tumor-antigen specific CD8+ T cells. CUE-101, the first Immuno-STAT in clinical trials, is composed of a human leukocyte antigen (HLA) complex, HLA-A*0201, a peptide epitope derived from the HPV16 E7 protein, and 4 molecules of reduced affinity human interleukin-2 (IL-2) designed to bind, expand, and activate HPV16-specific CD8+ T cells for the treatment of HPV16+ cancers.

Methods CUE-101-01 is a first-in-human study in patients with HLA-A*0201 genotype and HPV16+ recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). R/M HNSCC patients refractory to ≥ 1 platinum- or checkpoint-inhibitor-based systemic therapies received CUE-101 monotherapy. Patients with previously untreated PD-L1+ (CPS ≥ 1) R/M HNSCC received CUE-101 and pembrolizumab 200 mg. Therapy was administered every 3 weeks until disease progression or unacceptable toxicity. Escalating doses of CUE-101 monotherapy or in combination with pembrolizumab were evaluated, followed by expanded enrollment at the recommended phase 2 dose (RP2D). Objectives included evaluation of safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity.

Results As of July 25, 2022, 62 patients have received CUE-101 ranging from 0.06 to 8 mg/kg/dose. The most common adverse events included fatigue (46%), anemia (24%), chills (24%), and hyponatremia (22%). In the monotherapy dose escalation portion, a MTD was not identified, and 4 mg/kg was chosen as the RP2D based on PK, PD, and preliminary clinical activity. CUE-101 dose escalation from 1 to 4 mg/kg in combination with pembrolizumab 200 mg has been completed with no DLTs observed and expansion of CUE-101 at 4 mg/kg with pembrolizumab is ongoing. PK data demonstrate dose-dependent increases in drug exposure that are sustained upon repeat dosing. PD data demonstrate selected expansion of HPV-16 E711-20-specific CD8+ T cells in the peripheral blood. Of the 19 evaluable patients treated with CUE-101 monotherapy at the RP2D of 4 mg/kg, 1 patient experienced partial response (PR) and 7 stable disease (SD) for ≥ 12 weeks. Of the 10 evaluable patients treated with CUE-101 plus pembrolizumab, 3 patients experienced PR (2 confirmed) and 2 patients SD for ≥ 12 weeks.

Conclusions CUE-101 has a manageable safety profile and demonstrates activity alone and in combination with pembrolizumab.

Acknowledgements The authors would like to thank all the patients who are participating in this study. The study is sponsored by Cue Biopharma, in collaboration with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and support from LG Chem, Ltd., Seoul, South Korea.

Trial Registration ClinicalTrials. gov NCT03978689

Ethics Approval This study was approved by Ethics and Institutional Review Boards (IRBs) at all study sites. IRB reference numbers: Advarra Pro00037736 (Moffitt Cancer Center), IRB 52744 (Stanford University School of Medicine), HRPO# 201905108 (Washington University School of Medicine), DF/HCC IRB# 19-374 (Massachusetts General Hospital), WIRB STUDY00008948 (University of Washington, Seattle), IRB 191714 (Vanderbilt University Medical Center Vanderbilt-Ingram Cancer Center),

2019-087 Karmanos Cancer Institute, WIRB 2000026098 (Yale Cancer Center), 2019-0578 (The University of Texas MD Anderson Cancer Center), WIRB 1908869642 (University of Arizona Cancer Center), WIRB IRB00112341(Winship Cancer Institute/Emory University), IRB 20-073 (Memorial Sloan Kettering Cancer Center), IRB00255391 (Johns Hopkins University School of Medicine), IRB(IRBMED) HUM00165746 (University of Michigan Comprehensive Cancer Center), IRB0001113 (US Oncology Inc./Affiliated Oncologists, LLC), WCG IRB00000533 (Gabrail Cancer Center), IRB000001113 (George Washington University Cancer Center).

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.